Macrogenics (MGNX) EBITDA Margin Growth (5y) (2017 - 2026)
Macrogenics (MGNX) EBITDA Margin Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,289.00 |
| Dec 31, 2025 | -1,849.00 |
| Sep 30, 2025 | 22,355.00 |
| Jun 30, 2025 | 6,828.00 |
| Mar 31, 2025 | 81,302.00 |
| Dec 31, 2024 | 2,135.00 |
| Sep 30, 2024 | 25,141.00 |
| Jun 30, 2024 | -3,882.00 |
| Mar 31, 2024 | -9,757.00 |
| Dec 31, 2023 | -19,651.00 |
| Sep 30, 2023 | 23,237.00 |
| Jun 30, 2023 | -10,699.00 |
| Mar 31, 2023 | 91,257.00 |
| Dec 31, 2022 | -5,377.00 |
| Sep 30, 2022 | 2.38 Mn |
| Jun 30, 2022 | 231,097.00 |
| Mar 31, 2022 | 125,898.00 |
| Dec 31, 2021 | 27,848.00 |
| Sep 30, 2021 | 71,437.00 |
| Jun 30, 2021 | -18,066.00 |